Experts share the results from the first-in-human phase 1 study of this treatment, plus a preview of its upcoming phase 2 trial.
Nathan Bryson, PhD
Advertisement
Articles by Nathan Bryson, PhD
Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?
Advertisement
Latest Updated Articles
RE104: A Novel, Fast-Acting Psychedelic for Postpartum DepressionPublished: June 26th 2024 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Everything You Need to Know About the Approval of Lumateperone for Major Depressive Disorder
2
FDA Committee Meets on Generative AI Digital Mental Health Devices
3
Alixorexton for Treatment of Narcolepsy Type 2: New Positive Phase 2 Data
4
Placebo Response Rates Vary Across Psychiatric Disorders
5
